Epidermal growth factor receptor mutations in non-small-cell lung cancer:: Implications for treatment and tumor biology

被引:340
作者
Jänne, PA
Engelman, JA
Johnson, BE
机构
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Dept Med Oncol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
关键词
D O I
10.1200/JCO.2005.09.985
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic target for patients with non-small-cell lung cancer (NSCLC). However, despite its almost universal presence in NSCLC tumors, therapeutic inhibition of EGFR has resulted in significant tumor regressions in only 10% to 20% of patients. Several investigations over the last 12 months have uncovered somatic mutations in EGFR that underlie the sensitivity to EGFR inhibitors. NSCLC tumors and cell lines with EGFR mutations are exquisitely sensitive to the EGFR tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, and are biologically distinct from other forms of NSCLC. Somatic mutations in EGFR are found more frequently in patients with adenocarcinomas, nonsmokers, patients of Asian ethnicity, and in females. EGFR mutation detection is now becoming clinically available and is being incorporated into clinical treatment decisions and into the design of future clinical trials. Mutations in K-ras, a mediator of EGFR signaling, are mutually exclusive with EGFR mutations, and are associated with resistance to EGFR TKIs. In addition, secondary mutations, conferring resistance to EGFR TKIs, in patients with primary EGFR mutations once sensitive to EGFR TKIs, are beginning to be identified. The frequency of EGFR mutations, their impact on NSCLC biology, clinical treatment, and clinical trial design, as well as methods and limitations for mutation detection, will be reviewed. (c) 2005 by American Society of Clinical Oncology.
引用
收藏
页码:3227 / 3234
页数:8
相关论文
共 53 条
[1]  
Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO
[2]  
2-H
[3]   Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer [J].
Argiris, A ;
Mittal, N .
LUNG CANCER, 2004, 43 (03) :317-322
[4]  
Brabender J, 2001, CLIN CANCER RES, V7, P1850
[5]   Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results [J].
Breathnach, OS ;
Freidlin, B ;
Conley, B ;
Green, MR ;
Johnson, DH ;
Gandara, DR ;
O'Connell, M ;
Shepherd, FA ;
Johnson, BE .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1734-1742
[6]   Trimodality treatment in stage III nonsmall cell lung carcinoma -: Prognostic impact of K-ras mutations after neoadjuvant therapy [J].
Broermann, P ;
Junker, K ;
Brandt, BH ;
Heinecke, A ;
Freitag, L ;
Klinke, F ;
Berdel, WE ;
Thomas, M .
CANCER, 2002, 94 (07) :2055-2062
[7]   A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].
Cools, J ;
DeAngelo, DJ ;
Gotlib, J ;
Stover, EH ;
Legare, RD ;
Cortes, J ;
Kutok, J ;
Clark, J ;
Galinsky, I ;
Griffin, JD ;
Cross, NCP ;
Tefferi, A ;
Malone, J ;
Alam, R ;
Schrier, SL ;
Schmid, J ;
Rose, M ;
Vandenberghe, P ;
Verhoef, G ;
Boogaerts, M ;
Wlodarska, I ;
Kantarjian, H ;
Marynen, P ;
Coutre, SE ;
Stone, R ;
Gilliland, DG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214
[8]  
EBERHARD DA, IN PRESS J CLIN ONCO, V23
[9]   ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines [J].
Engelman, JA ;
Jänne, PA ;
Mermel, C ;
Pearlberg, J ;
Mukohara, T ;
Fleet, C ;
Cichowski, K ;
Johnson, BE ;
Cantley, LC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) :3788-3793
[10]  
Fontanini G, 1998, CLIN CANCER RES, V4, P241